Brohee D, Vanhaeverbeek M, Kennes B, Neve P
Department of Internal Medicine, C.H.U. André Vésale (Université Libre de Bruxelles), Montigny-le-Tilleul, Belgium.
Mech Ageing Dev. 1991 May;58(2-3):127-38. doi: 10.1016/0047-6374(91)90087-g.
In this cross-sectional clinical study, it was found that two subtypes of CD5+ B-lymphocytes existed either with CD5-high and CD20-low or CD5-low and CD20-high expression, as determined by dual fluorescence analysis with fluorochrome-labeled monoclonal antibodies on a FACScan flowcytometer. In the normal healthy subjects (n = 20), the CD20 positive cells could be broken down into 3 subsets: CD5(2+) CD20+, 25.4 +/- 3.0% (mean +/- S.E.M.), CD5+ CD20(2+), 18.4 +/- 2.4% and CD5- CD20(2+), 56.2 +/- 2.7%. Similar values were observed in a group of patients (n = 29) suffering from a wide variety of benign or untreated malignant disorders. The CD5(2+) CD20+ subset was typically related to age (Spearman coefficient of correlation rho = 0.77, P less than 0.001 in healthy subjects and rho = 0.46, P = 0.02 in pathological cases). The CD5+ CD20(2+) subpopulation was a salient feature of newborns and little infants (n = 6, 75.4 +/- 2.4%, P less than 0.01). The CD5- CD20(2+) subset was characteristically depressed in patients treated with cytotoxics (n = 21, 41.2 +/- 3.6%, P = 0.001). As far as cytotoxic chemotherapy may represent a model of accelerated ageing, it is worth noting that, in patients treated with cytotoxics, the CD5 CD20 pattern was frequently disturbed in a hyperyoung or hyperaged picture. That age and cytotoxics can affect CD5 expression on CD20+ lymphocytes, suggests some specific B-dysregulation and should be put together with the known emergence of autoantibodies, paraproteinemias and lympho-plasmocytic tumors with age and chemotherapy.
在这项横断面临床研究中，通过在FACScan流式细胞仪上使用荧光染料标记的单克隆抗体进行双荧光分析发现，存在两种CD5 + B淋巴细胞亚型，其CD5高表达且CD20低表达或CD5低表达且CD20高表达。在正常健康受试者（n = 20）中，CD20阳性细胞可分为3个亚群：CD5(2+) CD20 +，25.4 +/- 3.0%（平均值 +/- 标准误），CD5 + CD20(2+)，18.4 +/- 2.4%，以及CD5 - CD20(2+)，56.2 +/- 2.7%。在一组患有各种良性或未经治疗的恶性疾病的患者（n = 29）中观察到了类似的值。CD5(2+) CD20 +亚群通常与年龄相关（健康受试者中Spearman相关系数rho = 0.77，P < 0.001；病理病例中rho = 0.46，P = 0.02）。CD5 + CD20(2+)亚群是新生儿和小婴儿的一个显著特征（n = 6，75.4 +/- 2.4%，P < 0.01）。CD5 - CD20(2+)亚群在用细胞毒性药物治疗的患者中明显降低（n = 21，41.2 +/- 3.6%，P = 0.001）。鉴于细胞毒性化疗可能代表一种加速衰老的模型，值得注意的是，在用细胞毒性药物治疗的患者中，CD5 CD20模式经常在超年轻或超老龄的情况下受到干扰。年龄和细胞毒性药物会影响CD20 +淋巴细胞上的CD5表达，这表明存在一些特定的B细胞失调，并且应该与已知的随着年龄和化疗出现的自身抗体、副蛋白血症和淋巴浆细胞瘤联系起来。
